New therapies, including antibody-drug conjugates, are revolutionizing treatment and extending survival in advanced urothelial carcinoma. Although the side effects of these new options require careful monitoring and management, bladder-preserving curative treatment for advanced urothelial carcinoma may finally become a reality.